Due to the established use of PSMA-PET in the staging and follow up of prostate cancer patients, and recognition of PSMA expression in a variety of other tumor entities, PSMA staining was also evaluated as a potential theragnostic target. Here, FOLH1 is linked to prostate carcinoma.